Perindopril
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
PERINDOPRIL: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Perindopril is an ACE inhibitor whose classic indication is hypertension and related renal protection. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, but this direction is currently supported only by mechanistic reasoning and 1 tangential publication — no clinical trials have been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (ACE inhibitor class; no formal approved-indication text available — drug is not registered in South Africa) |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data from DrugBank is not available. Based on the repurposing rationale accompanying this prediction, perindopril is known to act as an ACE inhibitor, blocking the conversion of angiotensin I to angiotensin II. This lowers intraglomerular pressure and is the classic pharmacological basis by which ACE inhibitors slow progression of hypertensive kidney damage.
Malignant hypertensive renal disease is an acute, severe subtype of hypertensive nephropathy. The link between perindopril’s general renal-protective mechanism in hypertension and this specific malignant subtype is therefore mechanistically plausible but not proven — it is extrapolated from general ACE-inhibitor class evidence rather than from studies conducted in this specific severe patient population.
Consequently, while the pharmacological rationale is sound in principle, the absence of dedicated trials in the malignant/accelerated hypertension subgroup — a population where rapid blood pressure control and careful renal monitoring are critical — means the prediction should be treated as a research hypothesis rather than a practice-ready repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36382821 | 2022 | Cohort/Case series | Urologiia (Moscow, Russia: 1999) | Examines renal function outcomes after nephrectomy for renal cancer, noting that outcomes depend on degree of renal function loss post-surgery. Relevance to perindopril or malignant hypertensive renal disease specifically is indirect — the paper does not evaluate the drug or this exact indication. |
South Africa Market Information
Perindopril currently has no SAHPRA registration on record in this dataset (0 licenses; market status: not marketed). No product or dosage form information is available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: TFDA/SAHPRA-equivalent labeling warnings and contraindications for this drug could not be retrieved for this evidence pack, which blocks a full initial safety assessment (see Next Steps).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to mechanistic reasoning (L4) plus a single publication that does not directly address perindopril’s use in malignant hypertensive renal disease, with no clinical trials identified. In addition, official product-label safety data (warnings/contraindications) is missing, which blocks a proper initial safety evaluation for this severe-acute patient population.
To proceed, the following is needed:
- Official TFDA/SAHPRA-approved Professional Information (warnings, contraindications) to complete initial safety screening
- Confirmed DrugBank mechanism-of-action data for perindopril
- Literature or trial evidence specific to ACE inhibitor use in malignant/accelerated hypertensive nephropathy (not general hypertensive nephropathy)
- Confirmation of SAHPRA registration status, since the drug currently shows as not marketed in this region
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.